Results 161 to 170 of about 50,222 (210)
Some of the next articles are maybe not open access.
Dacryocystorhinostomy with Intraoperative Mitomycin C
Ophthalmology, 1997To observe the effect of intraoperative mitomycin C on the size of the osteotomy site after dacryocystorhinostomy.:A total of 15 eyes of 14 patients diagnosed with primary acquired nasolacrimal duct obstruction were assigned randomly to either a mitomycin C group or a control group.
S C, Kao +4 more
openaire +2 more sources
Reductive activation of mitomycin C
Biochemistry, 1988Mitomycin C, an antitumor antibiotic, is known to require reductive activation in order to function as an alkylating agent. In this work reduction has been carried out by using radiolytically produced formate radicals that reduce mitomycin C to its semiquinone in a clean rapid one-electron reaction.
B M, Hoey, J, Butler, A J, Swallow
openaire +2 more sources
Mitomycin C in Photorefractive Keratectomy
Journal of Refractive Surgery, 2009Purpose: To evaluate the outcome of primary or retreatment photorefractive keratectomy (PRK) or photo-therapeutic keratectomy (PTK) with mitomycin C (MMC) 0.02% applied prophylactically intraoperatively for the prevention of haze and regression in cases of significant haze and regression after primary PRK, due to previous ...
Ashraf, Shalaby +2 more
openaire +2 more sources
American Journal of Clinical Oncology, 1984
The clinical spectrum and the pathological findings of renal toxicity in four patients treated with mitomycin-C are described. Our experience and evidence in the literature indicates that the renal impairment appears to be total-dose-related, with most patients developing renal symptoms after receiving at least 60 mg of mitomycin-C.
T S, Ravikumar +3 more
openaire +2 more sources
The clinical spectrum and the pathological findings of renal toxicity in four patients treated with mitomycin-C are described. Our experience and evidence in the literature indicates that the renal impairment appears to be total-dose-related, with most patients developing renal symptoms after receiving at least 60 mg of mitomycin-C.
T S, Ravikumar +3 more
openaire +2 more sources
Pharmacokinetics of intraperitoneal mitomycin C
Surgical Oncology Clinics of North America, 2003The favorable pharmacokinetics of MMC, used during intraperitoneal chemotherapy, has been reported in several studies [11-19]. A major safety issue in studies using intraperitoneal chemotherapy perfusion is the resulting systemic drug exposure. The AUCplasma is determined by the dose, the clearance, and the fraction absorbed from the peritoneal cavity.
S, van Ruth +2 more
openaire +2 more sources
Bioactivation and Resistance to Mitomycin C
2004Publisher Summary This chapter analyzes the bioactivation and resistance of tumor cells to mitomycin C (MC). MC is a naturally occurring antibiotic that was isolated originally from the microorganism Streptomyces caspitosus . MC exerts its antitumor activity primarily by damaging DNA through both monofunctional and bifunctional alkylations (cross ...
Helen A, Seow +3 more
openaire +2 more sources
Cancer chemotherapy and biological response modifiers, 1994
In conclusion, recent work has highlighted the fact that NSCLCs have elevated levels of NQO1 activity and that such an increase represents an excellent target for therapeutic exploitation. The 5-year survival rate seen with lung cancer is dismal and there is a high number of cancer deaths associated with this disease each year.
N W, Gibson, D, Ross
openaire +1 more source
In conclusion, recent work has highlighted the fact that NSCLCs have elevated levels of NQO1 activity and that such an increase represents an excellent target for therapeutic exploitation. The 5-year survival rate seen with lung cancer is dismal and there is a high number of cancer deaths associated with this disease each year.
N W, Gibson, D, Ross
openaire +1 more source